Lupin launches US FDA approved leflunomide tablets USP
02 September 2020 | News
The product would be manufactured at Lupin’s Pithampur (Unit I) facility in India
Image source: Shutterstock
Lupin Limited (Lupin), an innovation-led transnational pharmaceutical company headquartered in Mumbai has recently announced the launch of leflunomide tablets USP, 10 mg and 20 mg.
Having received approval from the United States Food and Drug Administration (U.S FDA) earlier, the product would be manufactured at Lupin’s Pithampur (Unit I) facility in India.
Leflunomide Tablets USP, 10 mg, and 20 mg, is the generic equivalent of Arava® Tablets, 10 mg, and 20 mg, of Sanofi-Aventis U.S LLC., and is indicated for the treatment of adults with active rheumatoid arthritis (RA).
Leflunomide Tablets USP (RLD: Arava®) had an annual sale of approximately USD 42 million in the U.S. (IQVIA MAT June 2020).
